On 12 - 13 June 2012, the Workshop to review and plan therapeutic efficacy surveillance (TES) in the Greater Mekong Sub-region was held in Kunming hotel, Yunnan province, China.
The WHO-Mekong Malaria Programme based in Bangkok, Thailand, SEARO (South-East Asia Regional Office), WPRO (WHO Western Pacific Region) and GMP HQ in close collaboration with the National Institute of Parasitic Diseases (NIPD) and Ministry of Health in Beijing, China organized the "Workshop to review and plan therapeutic efficacy surveillance (TES) in the Greater Mekong Sub-region". The attendees who took part in the workshop and reported therapeutic efficacy surveillance results in the last 4 years in GMS countries included the experts of WHO in Southeast Asia, Western Pacific, Vietnam, China, Laos, Burma, Thailand, Cambodia, Philippines, etc. and the other countries' partners from USAID, Institute of Malariology in Yunnan (China), Chinese CDC (Chinese Center for Disease Control and Prevention), leaders of National Institute of Malariology, Parasitology & Entomology, Institute of Parasitic Diseases, Institute of National Health, etc., the Principal Investigators and Co-principal Investigators in the field of anti-malarial drug surveillance in other countries, Chinese Ministry of Health, and so on.
The objectives of this workshop are:
· !important; To review drug resistance situation in GMS countries
· !important; To review implementation status of WHO TES protocol and results from the last 4 years
· !important; To finalize regional/country work and budget plan of TES in 2013-2014,
· !important; To discuss harmonization of drug resistance monitoring activities with other related projects
|
Delegates in the workshop |
WHO-MMP is keen to organize this meeting with WHO Regional Offices and taking leadership to coordinate USAID-funded partners (United States Agency for International Development_USAID) towards achieving Mekong strategic activities and products in the coming years as a contribution to further reduce malaria morbidity and mortality.